Axon Enterprise (NASDAQ:AXON) Receives "Market Outperform" Rating from JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Axon Enterprise (NASDAQ:AXON - Free Report) in a research report report published on Monday, Benzinga reports. JMP Securities currently has a $375.00 price objective on the biotechnology company's stock.

Several other research firms have also issued reports on AXON. Northland Securities boosted their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an outperform rating in a report on Thursday, August 8th. Bank of America initiated coverage on Axon Enterprise in a research report on Wednesday, July 17th. They set a buy rating and a $380.00 target price on the stock. Barclays boosted their price target on Axon Enterprise from $381.00 to $387.00 and gave the company an overweight rating in a research note on Wednesday, August 7th. Jefferies Financial Group assumed coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They issued a buy rating and a $385.00 price objective for the company. Finally, Needham & Company LLC reiterated a buy rating and set a $400.00 price objective on shares of Axon Enterprise in a report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat, Axon Enterprise presently has a consensus rating of Moderate Buy and an average target price of $358.08.

Axon Enterprise Trading Up 2.8 %

Shares of NASDAQ AXON traded up $9.77 during trading on Monday, reaching $364.39. The company had a trading volume of 755,857 shares, compared to its average volume of 519,635. The stock has a market cap of $27.54 billion, a P/E ratio of 106.55, a PEG ratio of 9.50 and a beta of 0.94. The company's fifty day moving average price is $332.91 and its 200-day moving average price is $312.13. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35. Axon Enterprise has a 12 month low of $189.12 and a 12 month high of $378.89.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business had revenue of $504.00 million for the quarter, compared to analysts' expectations of $478.35 million. During the same period in the prior year, the business posted $0.80 earnings per share. The firm's revenue was up 34.5% on a year-over-year basis. As a group, research analysts expect that Axon Enterprise will post 1.79 earnings per share for the current year.

Insider Buying and Selling

In other Axon Enterprise news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the firm's stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total transaction of $167,863.50. Following the transaction, the director now directly owns 7,379 shares in the company, valued at approximately $2,752,588.37. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Axon Enterprise news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the company's stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $373.03, for a total value of $167,863.50. Following the completion of the sale, the director now directly owns 7,379 shares of the company's stock, valued at approximately $2,752,588.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Matthew R. Mcbrady sold 2,000 shares of Axon Enterprise stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $364.66, for a total transaction of $729,320.00. Following the transaction, the director now directly owns 4,892 shares in the company, valued at approximately $1,783,916.72. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 278,650 shares of company stock worth $101,364,745. 6.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AXON. Blue Trust Inc. boosted its holdings in shares of Axon Enterprise by 987.5% in the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company's stock worth $27,000 after buying an additional 79 shares during the last quarter. ICA Group Wealth Management LLC purchased a new position in Axon Enterprise in the fourth quarter valued at about $26,000. Trivant Custom Portfolio Group LLC bought a new position in shares of Axon Enterprise during the 1st quarter valued at approximately $31,000. First PREMIER Bank purchased a new stake in shares of Axon Enterprise during the 1st quarter worth approximately $33,000. Finally, Blue Bell Private Wealth Management LLC bought a new stake in shares of Axon Enterprise in the 1st quarter worth approximately $41,000. Institutional investors own 79.08% of the company's stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.